Sajid Khan, PhD
I am an Assistant Professor/Research in the Department of Biochemistry & Structural Biology at the Long School of Medicine. Prior to joining UT Health San Antonio, I was a Research Assistant Professor in the department of pharmacodynamics at the University of Florida, Gainesville, FL. I completed my postdoc training in cancer therapeutics and translational research from the University of Arkansas for Medical Sciences (Little Roc, AR) and the University of Florida between 2016 to 2021.
- 2017 - Ph.D. - Biological Sciences (Cancer Biology) - CSIR-Central Drug Research Institute/Jawaharlal Nehru University, India
- 2011 - M.Sc. - Biotechnology - Aligarh Muslim University, India
- 2009 - B.Sc. - Biology/Chemistry - Aligarh Muslim University, India
- 2021 - Postdoctoral training - Translational Cancer Research - University of Florida, Gainesville, FL
- 2018 - Postdoctoral training - Translational Cancer Research - University of Arkansas for Medical Sciences, Little Rock, AR
- 2022 - Assistant Professor/Research - Department of Biochemistry & Structural Biology, Long School of Medicine, UT Health San Antonio, TX
- 2021 - 2022 - Research Assistant Professor - Department of Pharmacodynamics, College of Pharmacy, University of Florida, Gainesville, FL
Research & Grants
My research focuses on understanding the apoptosis mechanisms in cancer cells and targeting anti-apoptotic BCL-2 family proteins (such as BCL-XL, BCL-2 and MCL-1) using Proteolysis-Targeting chimeras (PROTACs) for effective cancer therapy. Furthermore, I study the therapeutic efficacy of BCL-2 protein inhibitors and PROTACs against different cancers including Leukemia, breast, colorectal, pancreatic and lung cancers. My other research goals involve understanding the resistance mechanisms to BCL-XL PROTACs and other targeted drugs as well as identifying novel combination therapies against difficult-to-treat cancers.
Title: Inhibition of Bcl-xL by Targeted Degradation
Project Number: R01 CA241191
Name of PD/PI: Zheng (Contact PI), Konopleva, & Zhou
Source of Support: NIH/NCI
Project/Proposal Start and End Date: 04/2020 – 03/2025
Title: Use of BCL-xL proteolysis targeting chimeras to treat pancreatic cancer
Project Number: R01 CA242003
Name of PD/PI: Zhou, Trevino, & Zheng (Contact PI)
Source of Support: NIH/NCI
Project/Proposal Start and End Date: 09/2019 – 08/2024
Title: Role of Senescent Cells in Radiation-induced Pulmonary Fibrosis
Project Number: R01 CA219836
Name of PD/PI: Zhou
Source of Support: NIH/NCI
Project/Proposal Start and End Date: 07/2017 – 07/2022
- Khan S, Zhang X, Lv D, Zhang Q, He Y, Zhang P, Liu X, Thummuri D, Yuan Y, Wiegand JS, Pei J, Zhang W, Sharma A, McCurdy CR, Kuruvilla VM, Baran N, Ferrando AA, Kim Y-M, Rogojina A, Houghton PJ, Huang G, Hromas R, Konopleva M, Zheng G, Zhou D. A selective BCL-XL PROTAC degrader achieves safe and potent antitumor activity. Nature Medicine. 2019, 25:1938–1947. PMCID: PMC6898785
- Khan S*, Weigand J, Zhang P, Hu W, Thummuri D, Budamagunta V, Hua N, Jin L, Allegra CJ, Kopetz SE, Zajac-Kaye M, Kaye FJ, Zheng G, Zhou D*. A BCL-XL PROTAC degrader DT2216 synergizes with KRASG12C inhibitors in preclinical models of KRASG12C–mutated cancers. Journal of Hematology & Oncology. 2022, 15:23. (*co-corresponding author). PMCID: PMC8905794
- Thummuri D*, Khan S*, Underwood PU*, Zheng P, Wiegand J, Zhang X, Budamagunta V, Sobh A, Tagmount A, Loguinov A, Riner AN, Akki AS, Williamson E, Hromas R, Vulpe C, Zheng G, Trevino JG, Zhou D. Overcoming Gemcitabine Resistance in Pancreatic Cancer Using the BCL-XL Specific Degrader DT2216. Molecular Cancer Therapeutics. 2022, 21:184-192. (*co-first author). PMCID: PMC8742767
- Lv D, Pal P, Liu X, Jia Y, Thummuri D, Zhang P, Hu W, Pei P, Zhang Q, Zhou S, Khan S, Zhang X, Hua N, Yang Q, Arango S, Zhang W, Nayak D, Olsen S, Weintraub S, Hromas R, Konopleva M, Yuan Y, Zheng G, Zhou D. Development of a BCL-xL and BCL-2 dual degrader with improved anti-leukemic activity. Nature Communications. 2021,12:6896. PMCID: PMC8617031
- Pal P, Thummuri D, Lv D, Liu X, Zhang P, Hu W, Poddar S, Hua N, Khan S, Yuan Y, Zhang X, Zhou D, Zheng G. Discovery of a Novel BCL-XL PROTAC Degrader with Enhanced BCL-2 Inhibition. Journal of Medicinal Chemistry. 2021, 64:14230-14246. PMCID: PMC8900268
- Kolb R, De U, Khan S, Luo Y, Kim M-C, Yu H, Wu C, Mo J, Zhang X, Zhang P, Zhang X, Borcherding N, Koppel D, Fu Y-X, Zheng SG, Avram D, Zheng G, Zhou D, Zhang W. Proteolysis-targeting chimera against BCL-XL destroys tumor-infiltrating regulatory T cells. Nature Communications. 2021, 2:1281. PMCID: PMC7904819
- Khan S, He Y, Zhang X, Yuan Y, Pu S, Kong Q, Zheng G, Zhou D. PROteolysis TArgeting Chimeras (PROTACs) as Emerging Anticancer Therapeutics. Oncogene, 2020, 39:4909-4924. PMCID: PMC7319888
- He Y*, Khan S*, Huo Z, Lv D, Zhang X, Liu X, Yuan Y, Hromas R, Xu M, Zheng G, Zhou D. Proteolysis targeting chimeras (PROTACs) are emerging therapeutics for hematologic malignancies. Journal of Hematology & Oncology. 2020, 13:103. PMCID: PMC7384229. (*co-first author)
- He Y, Koch R, Budamagunta V, Zhang P, Zhang X, Khan S, Thummuri D, Ortiz YT, Zhang X, Lv D, Wiegand JS, Li W, Palmer AC, Zheng G, Weinstock DM, Zhou D. DT2216-a Bcl-xL-specific degrader is highly active against Bcl-xL-dependent T cell lymphomas. Journal of Hematology & Oncology. 2020, 13:95. PMCID: PMC7364785
- Khan S, Shukla S, Sinha S, Meeran SM. Centchroman altered the expressions of tumor‐related genes through active chromatin modifications in mammary cancer. Molecular Carcinogenesis. 2016, 55:1747-1760.
- Khan S, Shukla S, Sinha S, Lakra AD, Bora HK, Meeran SM. Centchroman suppresses breast cancer metastasis by reversing epithelial-mesenchymal transition via downregulation of HER2/ERK1/2/MMP-9 signaling. The International Journal of Biochemistry & Cell Biology. 2015, 58:1-16.
- Dighe SU*, Khan S*, Soni I, Jain P, Shukla S, Yadav R, Sen P, Meeran SM, Batra S. Synthesis of β- Carboline-Based N-Heterocyclic Carbenes and Their Antiproliferative and Antimetastatic Activities against Human Breast Cancer Cells. Journal of Medicinal Chemistry. 2015; 58:3485–99. (*co-first author)
- Khan S, Shukla S, Sinha S, Meeran SM. Role of adipokines and cytokines in obesity-associated breast cancer: Therapeutic targets. Cytokine & Growth Factor Reviews. 2013, 24(6):503-13.